Research

Energy balance

Expanded Medicare coverage for GLP-1 receptor agonists (GLP-1RAs) for obesity treatment is projected to increase total Medicare drug costs by $65.9 billion over 10 years.

Practitioners should be aware of the significant projected costs associated with GLP-1RA coverage under Medicare.

StrongSupportsmedium confidence
Medicare's total drug costs were projected at $65.9 billion.
Jennifer H. Hwang et al. · JAMA Health Forum · 2025

Why this rating

Based on the economic evaluation design stated in the abstract.

Source

Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity

Jennifer H. Hwang et al. · JAMA Health Forum · 2025

DOI 10.1001/jamahealthforum.2025.0905

other · n=30000000Cited 27×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →